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Strengths and limitations of this study
 ► This is a pilot trial that will inform the design of a 
larger trial comparing rituximab versus standard 
care in MN with heavy proteinuria (>3.5 g/24 hours); 
being a pilot study, this study will not address inter-
vention questions.
 ► Complete remission of proteinuria (primary end- 
point) is a clinically important and more frequent 
outcome than kidney failure (final outcome). A trial 
looking at kidney failure for outcome may not be 
feasible.
 ► Recruitment potential of a trial comparing rituximab 
to cyclophosphamide is unknown; we will provide 
preliminary estimates and reasons for exclusion 
which may be used to increase the feasibility of a 
larger study.
ABSTRACT
Introduction Primary membranous nephropathy (MN) 
is a common cause of nephrotic syndrome in adults. The 
disease may have different long- term outcomes. After 10 
years of follow- up, 35%–50% of the untreated patients 
with persistent nephrotic syndrome may die or progress to 
end stage renal disease. The 2012 KDIGO (Kidney Disease 
Improving Global Outcomes) guidelines recommend that 
initial therapy should consist of alternating steroids and 
an alkylating agent for 6 months. Recent observational 
studies showed that the anti- CD20 antibody rituximab 
may be effective in inducing remission. We designed a 
pilot multicentre randomised trial to inform the design of 
a larger trial testing the efficacy and safety of treatment 
with steroids and cyclophosphamide versus rituximab 
in patients with primary MN and heavy proteinuria 
(>3.5 g/24 hours).
Methods and analysis This pilot, open- label, two- 
parallel- arm, randomised clinical trial will enrol 70 patients 
with primary MN and heavy proteinuria. Patients will be 
randomised in a 1:1 ratio to either the intervention arm 
(rituximab) or the active comparator arm (corticosteroid/
alkylating- agent therapy). The study will provide estimates 
of the probability of complete remission of proteinuria and 
risk of serious side effects at 12 months to inform the 
design of a larger trial. We will also assess the recruitment 
potential of each participating centre to address study 
feasibility.
Ethics and dissemination The trial received ethics 
approval from the local ethics boards. We will publish pilot 
data to inform the design of a larger clinical trial.
Trial registration numbers NCT03018535; 2011-
006115-59.
InTRoduCTIon
Primary membranous nephropathy (MN) 
is a common cause of nephrotic syndrome 
in adults. MN is an autoimmune disease 
mediated by the deposition of antibodies 
(usually IgG4) produced by autoreactive B 
cells directed against antigens located in the 
subepithelial area of the glomerular base-
ment membrane. In 60%–70% of patients 
with primary MN, the antibodies are directed 
against the receptor1 of phospholipase A2 
(PLA2R)1 2 ; in 10% of patients, circulating 
antibodies against thrombospondin type-1 
domain- containing 7A (THSD7A) have 
been detected.3 4 Additional autoantibodies 
of unknown clinical significance directed to 
podocyte neo- expressed cytoplasm proteins 
have been described, including aldose reduc-
tase, Mn- superoxide dismutase (SOD2) and 
alpha- enolase (alpha- ENO).5
The disease has heterogeneous outcomes. 
A complete or partial remission of protein-
uria may develop spontaneously in 30%–50% 
of patients,6 7 but relapses may occur and a 
number of patients will continue to have 
proteinuria and progress slowly. In longer 
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follow- up studies (10 years or more), 35%–50% of the 
untreated patients may die or progress to end- stage 
kidney failure.8–11
The pathogenetic background of MN suggests that 
there is a rationale to stop the production of these auto-
antibodies with therapies targeting B cells. A number of 
different treatments have been used in MN, including 
corticosteroids, cyclophosphamide, calcineurin inhibi-
tors and AdrenoCorticotropichormone (ACTH). Based 
on evidence from randomised controlled trials of the 
effect of alternating steroids and alkylating agent on 
disease remission and long- term progression, the 2012 
KDIGO (Kidney Disease Improving Global Outcomes) 
guidelines recommend that initial therapy consist of a 
6- month course of alternating monthly cycles steroids and 
an oral alkylating agent, preferably cyclophosphamide.12 
However, cyclophosphamide use increases the risk of 
myelotoxicity, infection and cancer. The ideal treatment 
of MN should target the B cells but display a more favour-
able safety profile.
In the last years, a therapy based on the anti- CD20 
monoclonal antibody rituximab has been successfully 
used in MN.13–15 While a randomised clinical study testing 
whether treatment with rituximab is non- inferior to cyclo-
sporine (second line therapy) in inducing long- term 
remission of proteinuria in patients with MN has recently 
been published,16 there is no head- to- head comparison 
in a randomised controlled trial between rituximab and 
gold standard treatment (cyclical corticosteroid/cyclo-
phosphamide therapy).
For this, we planned a pilot multicentre randomised 
trial to inform the design of a larger trial testing the effi-
cacy and safety of treatment with steroids and an alkylating 
agent versus rituximab in patients with primary MN and 
heavy proteinuria.
METhodS And dESIgn
design of the study
This is an open- label, two- parallel- arm, pilot randomised 
controlled trial assessing the recruitment potential of each 
participant centre and providing estimates of the possible 
benefits of rituximab versus cyclical corticosteroid/cyclo-
phosphamide therapy in inducing disease remission. Esti-
mates from this pilot will not address the clinical question 
of efficacy but will inform the feasibility and design of a 
larger trial. We will study complete remission of protein-
uria at 12 months (primary objective) in patients with 
MN and heavy proteinuria, and other outcomes. After 3 
months of therapy with renin- angiotensin system (RAS) 
inhibitors and reduction of blood pressure <130/80 mm 
Hg (run- in/conservative phase of the study), patients with 
estimated Glomerular Filtration Rate (GFR) ≥30 mL/min 
(Modification of Diet in Renal Disease (MDRD) formula) 
and proteinuria >3.5 g/24 hours will be eligible for the 
study. We will follow participants up to 36 months.
Study enrolment has been completed in December 
2018.
Setting
Interventions will be administered in an inpatient setting 
at the following nephrology units: Montichiari (coordi-
nating centre), Bari, Cagliari, Messina, Viterbo, Gorizia, 
Bologna, Bern, Novara, Modena, Milano. Each partici-
pant will be followed at the same institution where the 
induction treatment will be administered.
Eligibility criteria
Inclusion criteria include: patients aged 18 years and 
older; biopsy- proven diagnosis of MN performed within 
24 months before enrolment; proteinuria >3.5 g/24 hours 
on three 24- hour urine collections (once a week for 
3 weeks following the run- in phase); estimated GFR 
≥30 mL/min/1.73 m2 (MDRD formula); postmenopausal 
females, or females surgically sterile or practising a medi-
cally approved method of contraception; blood pressure 
<130/80 mm Hg; Idrossimetilglutaril- CoA (HMG- CoA) 
reductase inhibitor therapy; RAS inhibition therapy.
Exclusion criteria include serum creatinine >2.0 mg/dL 
or estimated GFR <30 mL/min/1.73 m2; previous treat-
ment with rituximab, steroids, alkylating agents, calci-
neurin inhibitors, synthetic ACTH, Micofenolate Mofetil 
(MMF), azathioprine; presence of active infection; 
secondary cause of MN (eg, hepatitis B and C, Systemic 
Lupus Erythematosus (SLE), medications, malignancies; 
testing for HIV, hepatitis B and C should have occurred 
<6 months prior to enrolment into the study); type 1 or 2 
diabetes mellitus; pregnancy or nursing for safety reasons; 
renal vein thrombosis documented prior to entry by renal 
ultrasound (US) or CT scan.
Participant identification process
All patients affected by primary MN and proteinuria 
>3.5 g/24 hours followed by the participating institutions 
will be screened for eligibility. A local study coordinator 
will illustrate the project, deliver the information mate-
rial (information sheet and informed consent form) and 
collect written informed consent. Participants will be told 
that they will be able to withdraw consent at any time.
Randomisation
Participants will be randomised 1:1 to the intervention 
or active comparator arm. A distant site with no clinical 
involvement in the trial will generate a randomisation list. 
Assignments will be notified electronically after obtaining 
signed consent. A local study coordinator responsible 
for recruitment will assign a unique participant study 
number and request assignment from the institution 
responsible for randomisation. An analyst from a distant 
site, not involved in patient care, where the randomisa-
tion lists have been generated and kept concealed from 
the clinical investigators, will communicate the allocation 
arm to the study coordinator.
Treatment arms
Intervention
Patients randomised to the intervention arm will receive 
two courses of the chimeric monoclonal anti- CD20 
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antibody rituximab at a dose of 1 g on days 1 and 15 without 
concomitant or subsequent drug therapies. Rituximab will 
be diluted in 500 mL of normal saline and administered 
at 9 mL/hour for the first 30 min; thereafter, the infu-
sion rate will be doubled every 30 min up to a maximum 
of 72 mL/hour. In order to reduce common reactions, 
patients will receive a premedication with methylpred-
nisolone (2 mg/kg infused in 30 intravenous diluted in 
100 mL of normal saline), oral cetirizine (0.2 mg/kg) 
and oral paracetamol (15 mg/kg). Registered nurses will 
deliver the premedication and the intervention drug in 
the nephrology units of participating centres.
Active comparator
Patients randomised to active comparator will receive 
cyclical corticosteroid/cyclophosphamide therapy, 
consisting of three consecutive cycles of 2- month dura-
tion each (for a total of 6 months), one based on steroids 
and one based on cyclophosphamide. The first month of 
each 2 month cycle (months 1, 3 and 5) will begin with 
a 1 g pulse of intravenous methylprednisolone repeated 
daily for three consecutive days followed by oral methyl-
prednisolone (0.4 mg/kg/day) or prednisone (0.5 mg/
kg/day) for the remaining days of that month. In the 
second month of each 2- month cycle (months 2, 4 and 6), 
the steroid will be stopped and oral cyclophosphamide 
(2.0 mg/kg/day) will be given daily for that month.9
Relevant concomitant care
Any medications not listed in the exclusion criteria may 
be given at the discretion of the investigator. The inves-
tigator will record all concomitant medications taken 
by the participant in the appropriate section of the case 
report form.
outcomes
The primary outcome measure is complete remission 
(proteinuria to ≤0.3 g/day) at 1 year.17 The secondary 
end- points will be change from baseline in proteinuria at 
6, 12, 18, 24 and 36 months following treatment. We will 
estimate the probability of complete (primary outcome 
measure) or partial remission (reduction in proteinuria 
of at least 50% over the baseline and between 0.31 and 
3.5 g/day) at 6, 12, 18, 24 and 36 months. Other outcomes 
summarised at the same time points will include eGFR 
and serum creatinine level (mg/dL). We will summarise 
data on time to relapse of heavy proteinuria, the levels of 
autoantibodies and their relation to therapy and protein-
uria response in a subgroup of patients at baseline and 3 
days, 1 month, 3 months, 6 months and 12 months after 
treatment. We will summarise data on serious side effects: 
death, life- threatening event, hospitalisation, disability, 
quality of life, permanent impairment or damage. We will 
also assess the recruitment potential of a trial comparing 
rituximab to cyclophosphamide in MN, and track reasons 
for exclusion (including those who may be eligible but 
refuse to participate).
Safety data
We will collect any untoward medical occurrence in the 
form of signs, symptoms, abnormal laboratory finding 
or disease that emerge or worsen relative to baseline (ie, 
present at the initial study visit).
data collection methods and adherence during follow-up
Study visits will be done at baseline and after 3, 7, 14 days 
and 3, 6, 12, 24 and 36 months, unless complications or 
relapses occur. Determination of 24- hour proteinuria will 
be performed at baseline and after 1, 3, 6, 12, 24 and 36 
months at a local laboratory. Complete blood count will 
be evaluated at baseline, after 3 and 7 days and at 3, 6, 
12, 24 and 36 months. In patients undergoing cyclical 
therapy, during the administration of cyclophosphamide, 
monitoring blood cells will be performed every week, in 
order to prevent bone marrow toxicity. Kidney function, 
plasma proteins and cholesterol levels will be obtained at 
baseline and after 1, 3, 6, 12, 18, 24 and 36 months. Levels 
of anti- PLA2R (ELISA method), anti- THSD7A (IF assay) 
and anti- AR, anti- SOD2 and anti- alpha- ENO (ELISA 
method) auto- antibodies will be evaluated in a subgroup 
of patients at baseline and 3 days, 1 month, 3 months, 
6 months and 12 months after treatment. In patients 
undergoing rituximab, lymphocyte subpopulations (for 
CD20 lymphocytes B count) will be evaluated at baseline, 
after 3 days and after 3, 6, 9, 12, 18, 24 and 36 months. 
Time schedule of enrolment, interventions assessments 
and visits for participants are shown in figure 1. A local 
study coordinator will maintain ongoing contact with the 
patients to collect potential adverse events also in order 
to minimise loss to follow- up/dropout.
data management
The investigators will be responsible for recording study 
data in the case report form and entering study data in 
the electronic database prepared by the study coordi-
nating centre. The data management and analysis centre 
at the University of Calgary will be responsible for data 
processing and analysis. Database will be locked once 
quality assurance procedures have been completed.
Statistical methods
Analyses will be mainly descriptive and will focus on CI 
estimation. We will use standard statistical methods to 
summarise the sample characteristics overall and by arm 
assignment, using statistics for quantitative (mean and 
SD) and qualitative (frequencies) data as appropriate. We 
will do comparative analysis acknowledging the nature 
and purpose of this pilot study. Given the relatively small 
study size, its feasibility objective and the lack of a power 
calculation, we will treat any comparative analyses as 
preliminary and interpret them with caution. We expect 
that there could be imbalance in baseline covariates 
which would need adjustment in the analyses, and that 
the CIs will likely to be imprecise regardless of statistical 
testing results. Following this approach, we will consider 
the following analyses: logistic regression to compare 
by copyright.
 on M











pen: first published as 10.1136/bm






4 Scolari F, et al. BMJ Open 2019;9:e029232. doi:10.1136/bmjopen-2019-029232
Open access 
Figure 1 Schematic view of trial design. BP, blood pressure; ITT, intention to treat. ACEI- ARB, Angiotensin Coverting Enzyme 
Inhibitor- Angiotensin II receptor Blockers.
the probability of achieving complete remission at 12 
months and other binary outcomes, and methods for 
continuous, count or survival data for time to event anal-
yses (secondary outcome). In all analyses, we will use an 
intention- to- treat approach, whereby participants will be 
analysed as randomised regardless of protocol adherence. 
We will replace missing data in two ways: first carrying 
forward the last available measure; second, assuming the 
worst- case scenario by considering the missing data in the 
active comparator group as successes and missing data in 
the active intervention as failures.
Sample size
The main reason for conducting the present pilot study 
is to gather preliminary outcome data for the primary 
outcome measure (disease remission) in order to perform 
a sample size calculation for a larger trial.18 To estimate 
the probability of achieving complete remission in the 
two treatment groups, we will include 35 participants 
per arm, following a general rule of thumb (ie, at least 
30 statistical unit per parameter).18 We will follow partici-
pants for at least 1 year. We expect that each centre would 
enrol between 6 and 8 participants over 2 years. This pilot 
study will provide preliminary effect estimate to inform 
the design of a larger study, as it will not be powered to 
address intervention questions.
Patient and public involvement
Neither patients or the public were directly involved in 
the study design or conduct of the study. No plans were 
established a priori for sharing the results of the study 
with participants.
Study termination
Participants will be informed that they have the right 
to withdraw from the study at any time, without preju-
dice to their medical care. Any withdrawal will be fully 
documented in the case report form. Follow- up will be 
considered complete when the participant has completed 
all study procedures and assessments up to the month-12 
visit (primary end- point).Termination of receipt of study 
drug for a patient will be mandatory in the following situ-
ations: pregnancy, significant worsening of renal func-
tion (defined as doubling of serum creatinine), onset of 
malignancy, serious hypersensitivity or allergic reaction, 
any serious adverse events, serious intercurrent illness, 
administrative reasons, or investigator’s or participant’s 
request.
The study will continue from the enrolment of the first 
participant until 1 year from the enrolment of the last 
participant. Participants enrolled earlier will be followed 
for a longer period of time; the last participant will be 
followed for 1 year. Participant’s participation in the treat-
ment phase of the study will be stopped if any of the event 
mentioned above occurs. In these situations, patient’s 
participation in the study will be maintained for follow- up 
if the participant agrees to be followed for safety and 
outcome measures. We have no plans for interim anal-
yses or prespecified stopping rules. The Sponsor (Spedali 
Civili Hospital of Brescia) may temporarily or perma-
nently discontinue the study for safety, ethical, compli-
ance or other reasons; in this case, the main investigator 
will be responsible for promptly informing the Indepen-
dent Ethics Committee.
Study monitoring
The safety and monitoring board (Board of Safety; BoSa) 
at the Spedali Civili di Brescia Hospital will be responsible 
for study monitoring. The BoSa is an independent team 
with functional autonomy, specifically created for no 
profit studies, consisting of qualified personnel expert in 
clinical research methodology and not directly involved 
in the clinical study. The frequency of monitoring visits 
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will be determined by the site enrolment rate. On study 
completion, the study monitor will visit the site to conduct 
a study termination visit.
dISSEMInATIon
The completed randomised controlled trial study will be 
summarised in a final report accurately presenting the 
study objectives, methods, results, limitations of the study 
and interpretation of findings. The authors of this study 
protocol will inform the contributing investigators in 
advance about any plans to publish or present data. Any 
publication and presentation of the results (abstract in 
journals or newspapers, oral presentations, etc), either in 
whole or in part, by investigators or their representatives 
will require presubmission review by the authors of this 
study protocol and all coauthors.
dISCuSSIon
This is the first step towards a clinical trial comparing the 
effectiveness of rituximab versus gold standard therapy in 
MN with heavy proteinuria. Being a pilot study, this study 
will address feasibility and design questions, as opposed 
to intervention questions. This pilot randomised trial is 
needed to provide preliminary data on outcome frequen-
cies following each treatment strategy in comparable 
groups (ie, randomised groups), including benefits and 
harms.
A study with sample size large enough to ensure suffi-
cient power is not feasible. Baseline probabilities to 
achieve disease remission with standard therapy are based 
on estimates obtained decades ago, and we need more 
recent estimates on recruitment potential. We also do not 
have estimates of effects in comparable groups to inform 
power analysis for a larger study of efficacy. Recruitment 
may be challenging for the low incidence of MN, the high 
cost of rituximab (in the absence of pharma support) and 
the large off- label use of the drug by nephrologists.
This pilot study has strengths. We selected a high- risk 
population (MN with heavy proteinuria) and designed 
methods to reduce bias (randomised design, steps to 
ensure complete follow- up and blinding of outcome adju-
dicators to treatment assignment). Only centres with clin-
ical and research expertise in nephrology were engaged 
in the study. A careful collection of safety data has been 
implemented.
The study also has limitations. First, interventions are 
not blinded. Second, the primary end- point is a surrogate 
end- point rather than a clinically meaningful end- point. 
However, the laboratory- based measures we adopted to 
define disease remission are objective and predict more 
distant outcomes, particularly progression of kidney 
disease to kidney failure, usually observed after 10–20 
years of treatment exposure. While a very large multi-
national trial will be necessary to study these hard end- 
points, remission of proteinuria is an important outcome 
for the patients with MN.19 20
In summary, this study addresses a study design ques-
tion that is relevant to improve outcomes of adults with 
MN and heavy proteinuria. Results from this study will be 
key to the design of a larger trial, if feasible.
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